It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia

Diabetes and Metabolism

Volumn 36, Issue 2, 2010, Pages 91-96

  Valensi, P ^a   Cosson, E ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Cardiovascular risk; Coronary artery disease; Diabetes; Revascularization; Silent myocardial ischaemia

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DRUG ELUTING STENT; HIGH RISK PATIENT; HUMAN; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PROGNOSIS; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SCREENING; SILENT MYOCARDIAL ISCHEMIA;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS;

EID: 77953289594     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.01.001     Document Type: Review

References (54)

1. Goraya T.Y., Leibson C.L., Palumbo P.J., Weston S.A., Killian J.M., Pfeifer E.A., et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 40 (2002) 946-953
2. Cosson E., Guimfack M., Paries J., Paycha F., Attali J.R., and Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?. Diabetes Metab 29 (2003) 470-476
3. Cosson E., Guimfack M., Paries J., Paycha F., Attali J.R., and Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care 26 (2003) 1313-1314
4. Valensi P., Paries J., Brulport-Cerisier V., Torremocha F., Sachs R.N., Vanzetto G., et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 28 (2005) 2722-2727
5. Bax J.J., Young L.H., Frye R.L., Bonow R.O., Steinberg H.O., and Barrett E.J. Screening for coronary artery disease in patients with diabetes. Diabetes Care 30 (2007) 2729-2736
6. Puel J., Valensi P., Vanzetto G., Lassmann-Vague V., Monin J.L., Moulin P., et al. Identification of myocardial ischemia in the diabetic patient Joint ALFEDIAM and SFC recommendations. Diabetes Metab 30 (2004) 3S-18S
7. Bax J.J., Bonow R.O., Tschope D., Inzucchi S.E., and Barrett E. The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 48 (2006) 754-760
8. Beller G.A. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective?. J Am Coll Cardiol 49 (2007) 1918-1923
9. Miller T.D., Redberg R.F., and Wackers F.J. Screening asymptomatic diabetic patients for coronary artery disease: why not?. J Am Coll Cardiol 48 (2006) 761-764
10. Young L.H., Wackers F.J., Chyun D.A., Davey J.A., Barrett E.J., Taillefer R., et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 301 (2009) 1547-1555
11. Frye R.L., August P., Brooks M.M., Hardison R.M., Kelsey S.F., MacGregor J.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (2009) 2503-2515
12. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
13. Preis S.R., Hwang S.J., Coady S., Pencina M.J., D'Agostino Sr. R.B., Savage P.J., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119 (2009) 1728-1735
14. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
15. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
16. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
17. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
18. Pyorala K., Lehto S., De Bacquer D., De Sutter J., Sans S., Keil U., et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease Findings from the EUROASPIRE I AND II surveys. Diabetologia 47 (2004) 1257-1265
19. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
20. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
21. Stevens R.J., Kothari V., Adler A.I., and Stratton I.M. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101 (2001) 671-679
22. Cosson E, Chanu B, Nguyen MT, Balta C, Balta S, Paries J, et al. Valeur diagnostique et pronostique du score de l'UKPDS, des recommandations américaines et françaises dans le cadre de la recherche d'une ischémie myocardique silencieuse. Diabetes Metab 2009;35:O23 [abstract].
23. Miettinen H., Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in non diabetic and non-insulin-dependent diabetic subjects. Stroke 27 (1996) 2033-2039
24. Cosson E, Nguyen MT, Balta C, Paries J,Valensi P. Intérêt des recommandations Alfediam-SFC (RECO) sélectionnant les diabétiques à risque d'ischémie myocardique silencieuse (IMS). Une étude de suivi avec analyse des changements de pratique depuis 1992. Diabetes Metab 2008;34:O54 [abstract].
25. Aktas M.K., Ozduran V., Pothier C.E., Lang R., and Lauer M.S. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA 292 (2004) 1462-1468
26. Balady G.J., Larson M.G., Vasan R.S., Leip E.P., O'Donnell C.J., and Levy D. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation 110 (2004) 1920-1925
27. Jouven X., Empana J.P., Schwartz P.J., Desnos M., Courbon D., and Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 352 (2005) 1951-1958
28. Cole C.R., Foody J.M., Blackstone E.H., and Lauer M.S. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 132 (2000) 552-555
29. Lauer M., Froelicher E.S., Williams M., and Kligfield P. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise. Cardiac Rehabilitation, and Prevention. Circulation 112 (2005) 771-776
30. Valensi P., Nitenberg A., Sachs R., and Cosson S. Comment je traite et prends en charge une ischémie myocardique silencieuse. Le point de vue du diabétologue. J Annu Diabetol Hôtel Dieu (2006) 159-175
31. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
32. Pepine C.J., Cohn P.F., Deedwania P.C., Gibson R.S., Handberg E., Hill J.A., et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 90 (1994) 762-768
33. Davies R.F., Goldberg A.D., Forman S., Pepine C.J., Knatterud G.L., Geller N., et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95 (1997) 2037-2043
34. Faglia E., Manuela M., Antonella Q., Michela G., Vincenzo C., Maurizio C., et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am Heart J 149 (2005) e1-e6
35. Sorajja P., Chareonthaitawee P., Rajagopalan N., Miller T.D., Frye R.L., Hodge D.O., et al. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation 112 (2005) I311-I316
36. Davis K.B., Alderman E.L., Kosinski A.S., Passamani E., and Kennedy J.W. Early mortality of acute myocardial infarction in patients with and without prior coronary revascularization surgery. A Coronary Artery Surgery Study Registry Study. Circulation 85 (1992) 2100-2109
37. Berger P.B., Velianou J.L., Aslanidou Vlachos H., Feit F., Jacobs A.K., Faxon D.P., et al. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 38 (2001) 1440-1449
38. Shaw L.J., Berman D.S., Maron D.J., Mancini G.B., Hayes S.W., Hartigan P.M., et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 (2008) 1283-1291
39. Weintraub W.S., Spertus J.A., Kolm P., Maron D.J., Zhang Z., Jurkovitz C., et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359 (2008) 677-687
40. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118:2277-85 [7p following 85].
41. Stettler C., Allemann S., Wandel S., Kastrati A., Morice M.C., Schomig A., et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337 (2008) a1331
42. Farkouh M.E., Dangas G., Leon M.B., Smith C., Nesto R., Buse J.B., et al. Design of the Future Revascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 155 (2008) 215-223
43. Nitenberg A., Antony I., Aptecar E., Arnoult F., and Lerebours G. Impairment of flow-dependent coronary dilation in hypertensive patients. Demonstration by cold pressor test induced flow velocity increase. Am J Hypertens 8 (1995) 13S-18S
44. Nitenberg A., Ledoux S., Valensi P., Sachs R., and Antony I. Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients. Diabetes 51 (2002) 813-818
45. Nitenberg A., Ledoux S., Valensi P., Sachs R., Attali J.R., and Antony I. Impairment of coronary microvascular dilation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes 50 (2001) 1180-1185
46. Nitenberg A., Paycha F., Ledoux S., Sachs R., Attali J.R., and Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 97 (1998) 736-743
47. Nitenberg A., Pham I., Antony I., Valensi P., Attali J.R., and Chemla D. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis 183 (2005) 113-120
48. Sachs R.N., Valensi P., Lormeau B., Taupin J.M., Nitenberg A., Metz D., et al. Determinants of echocardiographically measured left ventricular mass in diabetic patients with or without silent myocardial ischaemia. Diabetes Metab 25 (1999) 128-136
49. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007;115:402-26.
50. Raggi P., Bellasi A., and Ratti C. Ischemia imaging and plaque imaging in diabetes: complementary tools to improve cardiovascular risk management. Diabetes Care 28 (2005) 2787-2794
51. Avignon A., Sultan A., Piot C., Mariano-Goulart D., Thuan Dit Dieudonne J.F., Cristol J.P., et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 30 (2007) 2934-2939
52. Albertini J.P., Valensi P., Lormeau B., Vaysse J., Attali J.R., and Gattegno L. Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients. Diabetes Care 22 (1999) 2044-2048
53. Cosson E, Nguyen M, Pham I, Pontet M, Nitenberg A,Valensi P. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients Diabet Med 2009;26:872-9.
54. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 (1995) 1235-1241